Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment

P. Kaufmann, HG. Cruz, A. Krause, I. Ulč, A. Halabi, J. Dingemanse,

. 2016 ; 82 (2) : 369-79. [pub] 20160510

Language English Country Great Britain

Document type Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18017314

AIM: The aim of the present study was to explore the effect of hepatic or renal dysfunction on the pharmacokinetics (PK), tolerability and safety of selexipag, an orally active prostacyclin receptor agonist. METHODS: Two prospective, open-label studies evaluated the PK of selexipag and its active metabolite ACT-333679 in healthy subjects and in subjects with mild, moderate and severe hepatic impairment or severe renal function impairment (SRFI). A single dose of 200 μg or 400 μg was administered. The PK parameters were derived from plasma concentration-time profiles. RESULTS: Exposure increased with the severity of hepatic impairment. Geometric mean ratios and 90% confidence intervals of the area under the concentration-time curve from time zero to infinity (AUC0-∞ ) for selexipag and ACT-333679 increased 2.1-fold (1.7-2.6) and 1.2-fold (0.9-1.6) in subjects with mild hepatic impairment, and 4.5-fold (3.4-5.8) and 2.2-fold (1.7-2.8) in subjects with moderate hepatic impairment when compared with healthy subjects. The two subjects with severe hepatic impairment showed similar dose-normalized exposure to that of subjects with moderate hepatic impairment. A 1.7-fold increase in the AUC0-∞ of selexipag and ACT-333679 was observed with SRFI compared with healthy subjects. Although exposure to selexipag and/or ACT-333679 was higher in subjects with mild or moderate hepatic impairment or SRFI vs. healthy subjects, no safety concerns were raised in these groups. CONCLUSIONS: Based on these observations, the PK data suggest that the clinically used starting dose needs no adjustments in patients with mild or moderate hepatic impairment or SRFI. However, doses should be up-titrated with caution in these patients. The small number of subjects limits the interpretation of selexipag PK in subjects with severe hepatic impairment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017314
003      
CZ-PrNML
005      
20180516140138.0
007      
ta
008      
180515s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bcp.12963 $2 doi
035    __
$a (PubMed)27062188
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kaufmann, Priska $u Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
245    10
$a Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment / $c P. Kaufmann, HG. Cruz, A. Krause, I. Ulč, A. Halabi, J. Dingemanse,
520    9_
$a AIM: The aim of the present study was to explore the effect of hepatic or renal dysfunction on the pharmacokinetics (PK), tolerability and safety of selexipag, an orally active prostacyclin receptor agonist. METHODS: Two prospective, open-label studies evaluated the PK of selexipag and its active metabolite ACT-333679 in healthy subjects and in subjects with mild, moderate and severe hepatic impairment or severe renal function impairment (SRFI). A single dose of 200 μg or 400 μg was administered. The PK parameters were derived from plasma concentration-time profiles. RESULTS: Exposure increased with the severity of hepatic impairment. Geometric mean ratios and 90% confidence intervals of the area under the concentration-time curve from time zero to infinity (AUC0-∞ ) for selexipag and ACT-333679 increased 2.1-fold (1.7-2.6) and 1.2-fold (0.9-1.6) in subjects with mild hepatic impairment, and 4.5-fold (3.4-5.8) and 2.2-fold (1.7-2.8) in subjects with moderate hepatic impairment when compared with healthy subjects. The two subjects with severe hepatic impairment showed similar dose-normalized exposure to that of subjects with moderate hepatic impairment. A 1.7-fold increase in the AUC0-∞ of selexipag and ACT-333679 was observed with SRFI compared with healthy subjects. Although exposure to selexipag and/or ACT-333679 was higher in subjects with mild or moderate hepatic impairment or SRFI vs. healthy subjects, no safety concerns were raised in these groups. CONCLUSIONS: Based on these observations, the PK data suggest that the clinically used starting dose needs no adjustments in patients with mild or moderate hepatic impairment or SRFI. However, doses should be up-titrated with caution in these patients. The small number of subjects limits the interpretation of selexipag PK in subjects with severe hepatic impairment.
650    _2
$a acetamidy $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000081
650    _2
$a acetáty $x farmakokinetika $7 D000085
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antihypertenziva $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000959
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nemoci ledvin $x komplikace $x patofyziologie $7 D007674
650    _2
$a nemoci jater $x komplikace $x patofyziologie $7 D008107
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a pyraziny $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D011719
650    _2
$a receptory epoprostenolu $x agonisté $7 D044006
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cruz, Hans G $u Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Krause, Andreas $u Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Ulč, Ivan $u CEPHA s.r.o. Komenského 19, CZ-323 00, Pilsen, Czech Republic.
700    1_
$a Halabi, Atef $u CRS-Clinical Research Services Kiel-GmbH, 24105, Kiel, Germany.
700    1_
$a Dingemanse, Jasper $u Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
773    0_
$w MED00000858 $t British journal of clinical pharmacology $x 1365-2125 $g Roč. 82, č. 2 (2016), s. 369-79
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27062188 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180516140313 $b ABA008
999    __
$a ok $b bmc $g 1300938 $s 1014154
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 82 $c 2 $d 369-79 $e 20160510 $i 1365-2125 $m British journal of clinical pharmacology $n Br J Clin Pharmacol $x MED00000858
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options